Spindle cell carcinoma of the breast: a case series of a rare histological subtype

Khan, Hamed; Wyld, Lynda; Dunne, Barbara; Lee, A.H.S; Pinder, Sarah; Evans, Andrew; Robertson, J. F. R.

doi:10.1016/s0748-7983(03)00107-0

Cited by 57 publications

(72 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with its potential role in neoplastic EMT, αB-crystallin expression is induced at an early stage during cardiac and skeletal muscle differentiation (mesodermal tissue) and protects myoblasts from apoptosis (10,40). Both early and late tumors were ER-negative, progesterone receptor-negative (PR-negative), and ErbB2/ HER-2-negative (data not shown) and resembled human metaplastic breast carcinomas, a histopathologic subtype notable for mesenchymal spindle cells mixed with epithelial glandular elements (41,42). Metaplastic carcinomas are also predominantly ER-, PR-, and ErbB2/HER-2-negative and frequently express vimentin and CK5 (43,44), an expression pattern shared by basal-like breast carcinomas.…”

Section: Discussionmentioning

confidence: 94%

B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

Moyano¹,

Evans²,

Chen³

et al. 2005

Journal of Clinical Investigation

266

282

View full text Add to dashboard Cite

Recent gene profiling studies have identified a new breast cancer subtype, the basal-like group, which expresses genes characteristic of basal epithelial cells and is associated with poor clinical outcomes. However, the genes responsible for the aggressive behavior observed in this group are largely unknown. Here we report that the small heat shock protein α-basic-crystallin (αB-crystallin) was commonly expressed in basal-like tumors and predicted poor survival in breast cancer patients independently of other prognostic markers. We also demonstrate that overexpression of αB-crystallin transformed immortalized human mammary epithelial cells (MECs). In 3D basement membrane culture, αB-crystallin overexpression induced luminal filling and other neoplastic-like changes in mammary acini, while silencing αB-crystallin by RNA interference inhibited these abnormalities. αB-Crystallin overexpression also induced EGF-and anchorage-independent growth, increased cell migration and invasion, and constitutively activated the MAPK kinase/ERK (MEK/ERK) pathway. Moreover, the transformed phenotype conferred by αB-crystallin was suppressed by MEK inhibitors. In addition, immortalized human MECs overexpressing αB-crystallin formed invasive mammary carcinomas in nude mice that recapitulated aspects of human basal-like breast tumors. Collectively, our results indicate that αB-crystallin is a novel oncoprotein expressed in basal-like breast carcinomas that independently predicts shorter survival. Our data also implicate the MEK/ERK pathway as a potential therapeutic target for these tumors.

show abstract

Section: Discussionmentioning

confidence: 94%

B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

Moyano¹,

Evans²,

Chen³

et al. 2005

Journal of Clinical Investigation

266

282

View full text Add to dashboard Cite

show abstract

“…Hormone and HER2 receptor positivity rates are also lower (0% to 26% for hormone receptors) in MpBC (Khan et al, 2003;Bae et al, 2011).…”

Section: Introductionmentioning

confidence: 94%

Metaplastic Breast Carcinoma: Case Series and Review of the Literature

Eşbah¹,

Türköz²,

Türker³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Metaplastic breast carcinoma (MpBC) is a rare disease entity, accounting for less than 1% of all breast carcinomas. Furthermore, it is a heterogenous disease with different subgroups, including malignant epithelial (carcinoma) and stromal ( Median 3 year progression free survival (PFS) and overall survival (OS) in this patients cohort were 33% and 56%, respectively. In conclusion, MpBC is a rare and orphan disease without standardized treatment approaches and the prognosis is poor so that larger studies to investigate different treatment schedules are urgently needed.

show abstract

“…que en el carcinoma no metaplásico y el tamaño inicial suele ser mayor (5 cm de media) 7,8,9 . Se presentan habitualmente en forma de masa palpable sin predilección por ningún cuadrante y con rápido crecimiento.…”

Section: Fig 3 400x (H-e)unclassified

“…En cuanto al pronóstico, el factor de riesgo más importante, influyendo claramente en la evolución, es el tamaño del tumor a la presentación, observándose que por encima de 5 cm el pronóstico empeora 11 . La mayoría de estudios llegan a la conclusión de que el pronóstico es peor que en los carcinomas no metaplásicos 3,6,9,11 , aunque hay algunos estudios en los que se concluye que el pronóstico es mejor 5,8 , probablemente por incluir casos con menor tamaño tumoral. …”

Section: Fig 3 400x (H-e)unclassified

Carcinoma metaplásico de mama: Revisión a propósito de un caso

Párraga¹,

Barandiaran²,

Aduriz³

et al. 2004

Oncología (Barc.)

View full text Add to dashboard Cite

Resumen• Propósito: presentamos un caso de carcinoma metaplásico de mama de nuestro centro, con revisión y discusión de la literatura.• Material y métodos: paciente de 79 años con carcinoma de células fusiformes de mama en cuadrante ínfero-interno de la mama izquierda. Se realizó tratamiento conservador con cuadrantectomía y radioterapia postquirúrgica. Describimos los hallazgos anatomo-patológicos.• Conclusiones: el carcinoma metaplásico de mama es más frecuente en mujeres mayores de 55 años, presentándose como una masa grande (5 cm) y de rápido crecimiento. Las áreas ganglionares suelen estar libres de enfermedad y los receptores hormonales suelen ser negativos. En cuanto al tratamiento, se tiende a tratar como el resto de carcinomas incluyéndolos en el grupo de alto riesgo para tratamiento complementario. Su pronóstico parece ser peor que los carcinomas convencionales de mama.

show abstract

Spindle cell carcinoma of the breast: a case series of a rare histological subtype

Cited by 57 publications

References 21 publications

B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

Metaplastic Breast Carcinoma: Case Series and Review of the Literature

Carcinoma metaplásico de mama: Revisión a propósito de un caso

Contact Info

Product

Resources

About